Synthace, a London, UK-based life sciences software company enabling scientists to automate biology experimentation and insight sharing in a unified, global R&D environment, raised $35m in Series C funding.
The round was co-led by Horizons Ventures and Sofinnova Partners.
The company intends to use the funds to accelerate commercial and go-to-market (GTM) growth, to expand its senior leadership team in the U.S., with new vice presidents of marketing and sales joining the U.S.-based CEO.
Led by Guy Levy-Yurista, Ph.D., CEO, Synthace is a life sciences software company enabling life science via an R&D cloud, a no-code software platform that addresses simplification, speed, and reproducibility for scientists thereby removing barriers to innovation. The platform automates experimentation and insight sharing so that scientists can focus on asking the most impactful questions to unlock the true potential of biology. It is used by global pharmaceuticals, high-growth biotech companies, leading CDMOs, and innovators in artificial intelligence.
FinSMEs
16/11/2021